• 제목/요약/키워드: Pancreatic diseases

검색결과 115건 처리시간 0.021초

내장신경 반복차단예에 대한 임상적 연구 (A Clinical Evaluation of Repeated Splanchic Nerve Block)

  • 성낙순;윤덕미;오흥근
    • The Korean Journal of Pain
    • /
    • 제3권2호
    • /
    • pp.108-118
    • /
    • 1990
  • Splanchnic nerve block (SNB) is performed to relieve intractable upper abdominal pain caused by carcinoma of the upper G-I tract. Not all patients achieve satisfactory pain relief; therefore, a second or third nerve block trial may need to be performed. In this study, an attempt was made to analyze the possible factors which might affect the result of repeated SNB in 42 the patients among 264 patients who received SNB at Severance Hospital during the period from January 1985 to December 1989. The results are as follows: 1) Among the 42 patients, including 30 males and 12 females, the fifties and forties were the major age groups. 2) Among the underlying diseases, stomach cancer was the most common (18 cases) and pancreatic cancer was next (14 cases). 3) The main locations of pain were the upper abdomen, epigastrium and entire abdomen in decreasing order. 4) Among the thirty-nine cases of first SNB combined with ascites, 13 cases received a repeat block, 81.0% of whom had had metastatic lesion. 5) There were 54.2% who had had single or combined treatment, operation, chemotherapy or radiotherapy before SNB. 6) Twently seven cases (64.3%) had received opioid medication for pain control. 7) In the 75% alcohol group, 11.7% of patients required a second block, and in the pure and 50% alcohol group, 9.6% of patients required a second block within two weeks of the first block. Three cases in both of these repeated block groups required a third block; representing 3.9%, of the 75% alcohol group and 1.6% of the pure and 50% alcohol group. 8) The volume of alcohol used was more than 16 ml bilaterally in both cases. 9) The points of the inserted needle were positioned in the upper and anterolateral part of the $L_1$ vertebra on both sides on the anteroposterior roentgenogram. The contrast media was spread upward along the anterior margin of the vertebral body and posteriorly in repeat block. The frequency of repeat block was higher in cases with ascites or metastasis. The instance of repeat block within 2 weeks of the first block was lower in the pure and 50% alcohol group than in the 75% alcohol group. Thus, alcohol concentration and patient status may be considered factors which influence the result of repeated SNB. We suggest early application of SNB in upper abdominal cancer patients.

  • PDF

미역줄나무 뿌리 추출물인 셀라스트롤의 비만관련 암증식 억제효과 (Anti-proliferative Effects of Celastrol, A Quinine Methide Triterpene Extracted from the Perennial Vine Tripterygium wilfordii, on Obesity-related Cancers)

  • 박선미;문현석
    • 한국식품위생안전성학회지
    • /
    • 제31권1호
    • /
    • pp.59-66
    • /
    • 2016
  • Celastrol은 미역줄나무의 뿌리에서 얻은 추출물로 오래전부터 관절염 및 자가면역 같은 염증반응 질병들을 치료하기 위하여 쓰여져 왔다. 이외에도 많은 연구들에서 celastrol이 신경보호, 항산화 및 알츠하이머 치료에 사용될 수 있으며 특히, 암 치료에 효과적이라고 밝혀 졌다(Table 1). 따라서 많은 연구자들이 생리학적, 생화학적 및 면역학적 관점에서 celastrol의 항암효과를 규명하고자 노력을 기울이고 있으며, 다양한 관점에서 신호전달체계를 조절한다는 사실을 밝혀냈다(Fig. 1). 특히, celastrol은 $NF-{\kappa}B$를 억제함으로서 암의 발달 및 전이를 저해함을 물론, 암의 치료에 동반되는 면역 반응을 조절 할 수 있다(Fig. 2). 또한 세포사멸과 관계된 유전자들을 활성화 시키고, 항세포사멸 유전자들을 억제시킴으로서 세포 주기를 조절한다. 유전자 조절 외에도 heat shock protein과 같은 단백질의 변조와 자가소화작용(autophagy)를 유도한다. 이처럼 celastrol의 다양한 효과는 암의 성공적 치료에 한발 더 가까워지게 만든다. 이외에도 celastrol의 항 비만 효과가 알려지면서 향후 비만 및 비만과 연계된 암 환자들이 가질 수 있는 부작용, 오남용 및 비용절감 측면에서 좋은 결과를 나타낼 것이라 예상 된다. Celastrol의 다양한 기작이 밝혀짐에도 불구 하고 직접적인 결합 부위에 대한 연구 결과는 아직 없으며, 임상적용 하기에 앞서 다양한 동물모델 in vivo 실험이 필요하다. 또한 임상치료 시도에 있어 안전성을 확보 하기 위해서는 celastrol의 단기간 및 장기간의 효과에 대한 깊은 연구가 요구된다.

Projection of Cancer Incidence and Mortality From 2020 to 2035 in the Korean Population Aged 20 Years and Older

  • Youjin, Hong;Sangjun, Lee;Sungji, Moon;Soseul, Sung;Woojin, Lim;Kyungsik, Kim;Seokyung, An;Jeoungbin, Choi;Kwang-Pil, Ko;Inah, Kim;Jung Eun, Lee;Sue K., Park
    • Journal of Preventive Medicine and Public Health
    • /
    • 제55권6호
    • /
    • pp.529-538
    • /
    • 2022
  • Objectives: This study aimed to identify the current patterns of cancer incidence and estimate the projected cancer incidence and mortality between 2020 and 2035 in Korea. Methods: Data on cancer incidence cases were extracted from the Korean Statistical Information Service from 2000 to 2017, and data on cancer-related deaths were extracted from the National Cancer Center from 2000 to 2018. Cancer cases and deaths were classified according to the International Classification of Diseases, 10th edition. For the current patterns of cancer incidence, age-standardized incidence rates (ASIRs) and age-standardized mortality rates were investigated using the 2000 mid-year estimated population aged over 20 years and older. A joinpoint regression model was used to determine the 2020 to 2035 trends in cancer. Results: Overall, cancer cases were predicted to increase from 265 299 in 2020 to 474 085 in 2035 (growth rate: 1.8%). The greatest increase in the ASIR was projected for prostate cancer among male (7.84 vs. 189.53 per 100 000 people) and breast cancer among female (34.17 vs. 238.45 per 100 000 people) from 2000 to 2035. Overall cancer deaths were projected to increase from 81 717 in 2020 to 95 845 in 2035 (average annual growth rate: 1.2%). Although most cancer mortality rates were projected to decrease, those of breast, pancreatic, and ovarian cancer among female were projected to increase until 2035. Conclusions: These up-to-date projections of cancer incidence and mortality in the Korean population may be a significant resource for implementing cancer-related regulations or developing cancer treatments.

마치현(馬齒莧)의 급성 췌장염 보호 효과 (Protective effects of Portulaca oleracea against cerulein-induced acute pancreatitis)

  • 곽태신;김동구;김주영;배기상;최선복;조일주;신준연;이성곤;김명진;김민준;송호준;박성주
    • 대한본초학회지
    • /
    • 제29권3호
    • /
    • pp.11-17
    • /
    • 2014
  • Objective : Portulaca oleracea (PO) has been used as an important traditional medicine for inflammatory and bacterial diseases in East Asia. However, the protective effects of PO on acute pancreatitis (AP) is not well-known. Therefore, this study was performed to identify the anti-inflammatory and prophylactic effects of PO on cerulein-induced AP. Methods : AP was induced in mice via intraperitoneal injection of supramaximal concentrations of the stable cholecystokinin analogue cerulein ($50{\mu}g/kg$) given every hour for 6 times. Water extracts of PO (100, 300, or 500 mg/kg) was administrated intra-peritoneally 1 h prior to the first injection of cerulein. The mice were killed at 6 h after the final cerulein injection. Pancreas and lung were rapidly removed for morphologic and histochemical examination, myeloperoxidase (MPO) assay. Blood samples were taken to determine serum amylase and lipase activities. Results : Administration of PO significantly inhibited pancreatic weight/body weight ratio, pancreas and lung histological injury. And MPO activity which indicates neutrophil infiltration was inhibited by PO extracts on cerulein-induced pancreatitis. In addition, PO administration inhibited digestive enzymes such as serum amylase and lipase activity on cerulein-induced pancreatitis. Conclusion : Our results could suggest that pre-treatment of PO reduces the severity of cerulein-induced AP, thereby, PO could be used as a protective agent against AP. Also, this study could give a clinical basis that PO could be a drug or agent to prevent AP.

담배 가격인상이 흡연률과 흡연귀속사망에 미칠 영향에 대한 연구 -대도시 일부 사무직 근로자를 대상으로- (A Study on The Effect of The Tobacco Price Raise on The Smoking Rate and Smoking Attributable Death)

  • 강종원;김정순
    • Journal of Preventive Medicine and Public Health
    • /
    • 제30권4호
    • /
    • pp.697-707
    • /
    • 1997
  • 본 연구에서는 대도시 일부 사무직 근로자를 대상으로 흡연에 관한 설문조사를 통해 흡연률, 과거흡연률, 가격변동시 예상흡연률과 그에 따른 흡연의 귀속 사망수 감소 기대수를 조사, 분석하였다. 그 결과는 다음과 같았다. 1. 대도시 지역 남성 사무직 근로자의 흡연률은 59.5%였고 과거흡연률은 28.8%였으며, 과거흡연자를 제외하고 흡연률을 산출할 경우 흡연률은 67.4%였다. 2. 남성흡연자중 담배의 가격과 무관하게 금연할 의사가 있다고 응답한 사람의 분율은 55.3%였고, 담배의 가격이 4배 이상 인상될 경우 금연하겠다고 응답한 사람의 분율은 61.5%로서 반수 이상의 흡연자가 금연하겠다는 의사를 가지고 있는 것으로 나타났다. 3. 남성 흡연자의 흡연시작연령은 반수 이상(62.3%) 만 20세 미만으로, 미성년자 시기에 흡연을 시작하는 경우가 많았다. 4. 담배의 가격인상폭을 크게 할수록 금연 의사가 있는 사람의 비율이 늘어서, 4배이상 가격을 인상할 경우 예상 흡연률이 26.7%였다. 매년 20%씩 담배의 가격이 오를 경우 예상 흡연률은 46.2%였다. 5. 남성을 대상으로 흡연과 관련이 깊은 주요 8개 질환군(폐암, 위암, 췌장암, 후두암, 식도암, 뇌혈관질환, 허헐성심질환, 만성폐쇄성폐질환)의 귀속위험을 추산한 결과 매년 25,863명이 흡연에 기인해서 사망하는 것으로 추산되었다. 이는 20세 이상 총 남성 사인 분류가능 사망수 128,875명의 20.1%이다. 6. 담배의 가격인상시 기대되는 흡연률을 적용하여 계산한 결과 담뱃값을 4배 이상 올렸을 때 금연 실천률을 100%로 가정했을 때 귀속위험은 13,527명으로서 매년 홉연으로 인한 사망의 47.7%인 12,336명의 사망을 줄일 수 있는 것으로 추산되었다. 7. 담배의 가격인상시 금연하도록 동기부여가 되는 사람중에서 실제로 금연하는 사람의 비율을 10%, 25%, 50%로 가정했을 때, 기대 사망수 감소는 가격을 4배 이상 인상했을 때 각각 1,112명, 3,483명, 5,796명 이었다.

  • PDF